Medtronic launches outcomes-based reimbursement program for MiniMed 670G system

This article was originally published here

Medtronic (NYSE:MDT) today launched an outcomes-based reimbursement program for its MiniMed 670G automated insulin delivery system.

As part of its ‘MiniMed 670G Performance Guarantee Program,’ the medtech giant will dole out flat-fee reimbursements of up to $25,000 per pump over four years for diabetes-related inpatient hospitalization and ER admissions.

Get the full story at our sister site, Drug Delivery Business News.

The post Medtronic launches outcomes-based reimbursement program for MiniMed 670G system appeared first on MassDevice.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply